Literature DB >> 31501912

[Fatigue, breathlessness and chest pain in a 31-year-old man with schizoaffective disorder].

L Mizera1, K Klingel2, M Gawaz1, S Greulich3.   

Abstract

BACKGROUND: Clozapine is an alternative antipsychotic medication used to control symptoms of schizophrenia and to reduce risks of suicidal behavior in patients who did not adequately respond to standard medication. Due to severe side effects including cardiomyopathy and myocarditis its clinical use is limited. CASE REPORT: A 31-year-old man of east European descent presented to the emergency medical department with fatigue, shortness of breath and chest pain. Due to a schizoaffective disorder he was treated with clozapine and lithium. Echocardiography revealed severely impaired left ventricular systolic function. After exclusion of coronary artery disease by coronary angiography an endomyocardial biopsy was performed according to the guidelines. This confirmed the clinically suspected toxic cardiomyopathy. Therefore, antipsychotic treatment was immediately changed and state of the art heart failure medication was started resulting in a clear improvement of left ventricular function.
CONCLUSION: In patients treated with clozapine or lithium and clinical signs of heart failure, toxic cardiomyopathy should be considered.

Entities:  

Keywords:  Biopsy, endomyocardial; Cardiomyopathies; Clozapine; Heart failure; Lithium

Mesh:

Substances:

Year:  2019        PMID: 31501912     DOI: 10.1007/s00108-019-00674-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  13 in total

1.  Clozapine and pericarditis with pericardial effusion.

Authors:  Aida Murko; Sarah Clarke; Donald W Black
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

2.  Cardiomyopathy Secondary to Long-Term Treatment With Lithium: A Case Report and Literature Review.

Authors:  Ángela Sofía Rosero Enríquez; Alejandro Ballesteros Prados; Alexandru S Petcu
Journal:  J Clin Psychopharmacol       Date:  2018-04       Impact factor: 3.153

3.  Myocarditis and cardiomyopathy associated with clozapine.

Authors:  J G Kilian; K Kerr; C Lawrence; D S Celermajer
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

Review 4.  Clozapine-induced myocarditis, a widely overlooked adverse reaction.

Authors:  K J Ronaldson; P B Fitzgerald; J J McNeil
Journal:  Acta Psychiatr Scand       Date:  2015-04-11       Impact factor: 6.392

5.  Dilated cardiomyopathy: an unusual complication of clozapine therapy.

Authors:  Badira Makhoul; Irit Hochberg; Shmuel Rispler; Zaher S Azzam
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-07-15

Review 6.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 7.  Systematic Review of Clozapine Cardiotoxicity.

Authors:  Martina Curto; Nicoletta Girardi; Luana Lionetto; Giuseppino M Ciavarella; Stefano Ferracuti; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-07       Impact factor: 5.285

8.  An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus.

Authors:  A Matsumori; C Kawai
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

9.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

10.  Selective Serotonin-norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy.

Authors:  Rahul Vasudev; Upamanyu Rampal; Hiten Patel; Kunal Patel; Mahesh Bikkina; Fayez Shamoon
Journal:  N Am J Med Sci       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.